Core Insights - Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics regarding potential securities fraud or unlawful business practices [1] - MoonLake reported disappointing results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [1] - Following the trial results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [1] Company Overview - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX [1] - The company is involved in the development of immunotherapeutic treatments, specifically focusing on sonelokimab [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past [2]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Rezolve AI PLC regarding potential securities fraud or unlawful business practices [1] - A report by Fuzzy Panda Research alleges that Rezolve misrepresents its AI capabilities and revenue growth, claiming it is primarily a mobile phone-related tech company [1] - Following the allegations, Rezolve's stock price dropped by $0.97, or 16.3%, closing at $4.98 per share [1] Group 1 - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [2] - The investigation focuses on whether Rezolve and its officers/directors engaged in fraudulent activities [1] - The Fuzzy Panda report specifically criticizes the CEO's history of false statements and the company's acquisition strategy of failing AI startups [1] Group 2 - The stock price decline occurred over two trading sessions following the release of the Fuzzy Panda report [1] - The investigation is part of a broader effort to protect investors' rights against corporate misconduct [2] - Pomerantz LLP has been active in the field for over 85 years, continuing the legacy of its founder in fighting for victims of corporate fraud [2]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [1]. Summary by Relevant Sections Class Action Details - Investors are encouraged to contact Pomerantz LLP to join the class action, with a deadline to appoint a Lead Plaintiff by November 17, 2025 [1]. - The lawsuit centers on whether Cytokinetics and its officers engaged in fraudulent activities concerning their securities [1]. FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting for aficamten's NDA [1]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [1]. - Following this announcement, Cytokinetics' stock price dropped by $5.57, or 12.98%, closing at $37.35 on May 2, 2025 [1]. - On May 6, 2025, CEO Robert I. Blum revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, leading to a further stock price decline of $2.70, or 7.36%, closing at $33.97 [1].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by DexCom, Inc. following allegations from a short report that highlighted serious issues with the company's G7 continuous glucose monitoring system [1][2]. Group 1: Investigation Details - Pomerantz LLP is representing investors of DexCom, Inc. and is looking into claims regarding possible securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Hunterbrook Media, which alleged that DexCom made unauthorized design changes to a critical component of its G7 glucose monitoring system, leading to serious health consequences for users [2]. Group 2: Market Reaction - Following the release of the Hunterbrook report, DexCom's stock price experienced a significant decline, falling by $8.99 per share, or 11.76%, closing at $67.45 per share on September 19, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Cybin Inc. and its officers or directors [1][3] Group 1: Investigation Details - The investigation is focused on claims made by investors of Cybin Inc. regarding possible violations of federal securities laws [3] - Following the announcement of Doug Drysdale stepping down as CEO on September 2, 2025, Cybin's stock price dropped by $1.24, or 16.58%, closing at $6.24 per share [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving PACS Group, Inc. and its officers or directors [1] Group 1: Company Developments - On September 8, 2025, PACS announced the resignation of Chief Financial Officer Derick Apt due to allegations of accepting high-value items from associated individuals, which violated company policies [3] - Following the announcement of the CFO's resignation, PACS's stock price dropped by $3.29 per share, a decline of 29.08%, closing at $8.03 per share on September 9, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Lesaka Technologies, Inc. and its officers or directors [1] Financial Disclosure - On September 10, 2025, Lesaka disclosed that its Audit Committee concluded that the unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, December 31, 2024, and March 31, 2025, should be restated due to a re-evaluation of revenue classification [3] - The company indicated that the previously reported financial statements should no longer be relied upon, impacting the classification of certain revenue as an agent rather than as a principal, along with related cost of goods sold [3] Market Reaction - Following the announcement of the financial restatement, Lesaka's stock price experienced a sharp decline during intraday trading on September 11, 2025 [3]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Synopsys, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Synopsys reported underperformance in its IP business and adopted a conservative outlook for Q4 while still guiding for another year of profitable growth [3] - Following the announcement, Baird downgraded Synopsys's rating from Outperform to Neutral and reduced its price target from $670 to $535 [3] - The stock price of Synopsys fell by $216.59, or 35.84%, closing at $387.78 per share on September 10, 2025, after the news [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Galiano Gold Inc. and its officers or directors [1] Group 1: Incident at Asanko Gold Mine - On September 9, 2025, Galiano reported a confrontation between community members and military personnel at its Asanko Gold Mine in Ghana, leading to civil unrest, a fatality, and damage to contractor equipment [3] - Following this incident, Galiano's stock price dropped by $0.18 per share, or 7.03%, closing at $2.38 per share on September 10, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Galiano Gold Inc. to investigate claims related to potential securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Celanese Corporation and its officers or directors, following disappointing financial results and significant stock price declines [1][4][5]. Financial Performance - In Q3 2024, Celanese reported adjusted earnings of $2.44 per share, below the consensus estimate of $2.84, and revenue of $2.65 billion, a 2.6% year-over-year decline, also missing the consensus estimate of $2.69 billion [3]. - For the full year 2024, Celanese reported a U.S. GAAP diluted loss per share of $13.86 and adjusted earnings per share of $8.37, with net sales of $10.3 billion, a 6% decrease from the previous year due to a 4% decline in price and a 1% decline in volume [4]. - In Q2 2025, Celanese's Engineered Materials segment continued to experience below-normal volumes due to destocking in Europe, leading to further disappointing financial results [5]. Stock Price Reaction - Following the Q3 2024 results, Celanese's stock price fell by $32.50, or 26.32%, closing at $91.00 on November 5, 2024 [3]. - After the Q4 and full year 2024 results, the stock price dropped by $15.00, or 21.46%, closing at $54.91 on February 19, 2025 [4]. - On August 12, 2025, the stock price fell by $6.20, or 13.07%, closing at $41.22 due to ongoing issues in the Engineered Materials segment [5].